SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The project is a derivative of Fartcoin. The Fartcoin deployer has deployed this token because the President at Bone Fide Wealth tweeted about "A client just called and asked me if there’s going to be a Fartcoin ETF this year." Since the Elon narrative is has been running this one has come to existence. The token is following different narratives like Fartcoin, SPX500 and other big memes following the Trump narrative.

Elon Trump Fart

ETF500.X is trending as the community rallies around the project, calling for a pump and highlighting its potential as the first ETF on Solana. Increased volume and accumulation are fueling optimism, though some caution against potential scams. Discussions also involve related meme coins like UPDOG and FARTCOIN.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is trending as the community anticipates potential gains, drawing attention to its connection with AI and autonomous agent technology. Grok's (Elon Musk AI) recommendations have fueled speculation about substantial returns, with community members actively discussing potential catalysts and real-world applications. The broader narrative focuses on Fetch.ai's role in the AI and crypto space, with some suggesting it's undervalued despite recent market fluctuations.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE.X is gaining traction as a community-driven meme coin, with many highlighting its solid community and potential for growth. Conversations revolve around its strong connection to internet culture and references to trending on UpDog. Investors are expressing bullish sentiment, anticipating further upward momentum.

The national debt has increased every year for the past ten years, and interest expenses have remained fairly stable due to low interest rates and the perceived low risk of U.S. government default, according to the U.S. Treasury Fiscal Data. This coin is a parody coin about the debt crises in the US and to highlight various aspects about this crises in a humouros way to the people on solana. $USNDC

UnitedStates National Debt Coin

UnitedStates National Debt Coin ($USNDC.X) is trending as community members highlight positive sentiment and strong buying activity. Conversations suggest a potential breakout, with many urging others to buy before a significant price increase. Some users are also discussing the coin's activity and tracking via Phantom wallet.

Mamo turns what used to be complex into easy, human-first routines.  It works quietly in the background, finding smart opportunities for your money while you focus on what matters in your life. Think of Mamo as your knowledgeable friend who understands how to help your money grow and explain everything in plain language.  Behind the scenes, Mamo applies proven strategies and real-time data to optimize your portfolio, reinvest earnings when conditions are right, and adapt to market shifts — all with your approval and full transparency.  No noise. No confusion. Just calm, steady growth.

Mamo

Mamo is trending as the community discusses its potential following a significant price run and subsequent pullback, with attention focused on the anticipated launch of The Base App in Q4. Some community members are speculating on price targets and the potential for substantial user growth once the app is released, while others express concerns about recent price action.

Solana Street Bets is not just a memecoin; it's a symbol of creativity, humor, and the power of a united community. Inspired by the infamous /wallstreetbets subreddit. Solana Street Bets is here to put respect on the Wall St originated memes in the industry. Solana Street Bets is a decentralized Solana meme coin inspired by the infamous /wallstreetbets subreddit.

SatoshiStreetBets

SSB.X is trending as community members highlight a specific associated token, $PUPU.X, with many claiming "dips are getting bought instantly" and momentum is building for a breakout. The project's connection to the broader SatoshiStreetBets community and a comparison to previous meme coin successes like PEPE are also driving interest. Bullish community members suggest that the "rocket fuel is stacking" for the project.

The Render Network is a leading decentralized GPU compute platform for applications ranging from 3D rendering to machine learning and generative AI.  The network connects node operators looking to monetize their idle GPU compute power with artists and developers looking to scale intensive 3D rendering work and machine learning applications in the cloud. Through a decentralized peer-to-peer network, the Render Network achieves unprecedented levels of scale, speed, and economic efficiency. Facilitated by the Render Network Foundation, the ecosystem empowers artists and developers to build services and applications for the emerging digital economy.

Render Token (SOL)

$RENDER.X is trending as users discuss its potential in the AI sector and speculate on possible catalysts. Some community members mention its connection to Grok AI and potential for significant gains, while others analyze its price action and discuss accumulation strategies. Conversations also address the token's migration to Solana and upcoming events like Rendercon.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc

Biogen ($BIIB) is trending as traders weigh the impact of a recent FDA roadblock for its Spinraza drug amid ongoing European regulatory reviews. The community is also actively discussing potential support trendlines and call option strategies. Positive sentiment stems from recent EU approval for Zurzuvae, a postpartum depression drug.

Plasma is the layer 1 blockchain building the stablecoin infrastructure for a new global financial system.   It is purpose-built for global stablecoin payments, offering zero-fee USD₮ transfers and custom gas tokens to help realise the stablecoin promise of permissionless access to financial services for everyone, everywhere.   Plasma’s global payments coverage and inbound suite of products position it as the native chain for stablecoin payments.

Plasma

Plasma (XPL.X) is trending amid community discussions about its trading volume and potential connections to other cryptocurrencies. Some traders are suggesting short positions based on technical analysis, while others express concerns about the project's activity and tokenomics, with comparisons being drawn to other stablecoins and yield protocols. The community is also actively speculating about price targets and the potential impact of new exchange listings.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending as investors discuss the company's recent acquisition of anti-coagulant assets, including a Pre-Phase-2 drug, which expands their pipeline. Community members are noting the bullish setup, breakout energy, and building momentum, anticipating a potential upside breakout. The company's advancements in cardiovascular therapeutics and potential impact on the anticoagulation market are also being highlighted.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nurix Therapeutics (NRIX) Soars 5.6%: Is Further Upside Left in the Stock?

Nurix Therapeutics (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -26.87% and -32.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Guardant Health (GH) Reports Q2 Loss, Beats Revenue Estimates

Guardant Health (GH) delivered earnings and revenue surprises of +15.38% and +9.77%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

EyePoint Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Latest Ratings for EYPT
 DateFirmActionFromTo Nov 2021HC Wainwright & Co.MaintainsBuy May 2021HC Wainwright & Co.MaintainsBuy Jan 2021Cantor FitzgeraldInitiates Coverage OnOverweight
 View More...

Shares of 4D Molecular Therapeutics Inc. (FDMT) plummeted over 35% to $17.30 by Wednesday afternoon, marking it as the top loser among U.S. stocks. Surprisingly, retail traders remain highly bullish on the stock, with Stocktwits sentiment extremely bullish (85/100) amid extremely high message volumes (95/100).<figure class="image"><img style="aspect-ratio:1308/308;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/FDMT_Sentiment_Meter_On_Jul_17_5f2f85024d.png" alt="FDMT Stocktwits Sentiment Meter On Jul 17" width="1308" height="308"><figcaption>FDMT Stocktwits Sentiment Meter On Jul 17</figcaption></figure>Initially, FDMT shares climbed following the release of encouraging mid-stage clinical study results for its 4D-150 gene therapy, aimed at treating wet age-related macular degeneration (wAMD), a chronic eye disorder that leads to blurred vision or blind spots in central vision.However, the broader market turned its focus to various downside risks, including safety concerns raised by RBC Capital. While the firm maintains 4D-150 is "best in class," it flagged a "safety blip" – one case of inflammation in a patient with a history of syphilis, Investing.com <a href="https://in.investing.com/news/stock-market-news/4d-molecular-therapeutics-tumbles-following-midstage-clinical-study-results-432SI-4316187">reported</a>. BMO Capital lowering the price target further may have added to the pressure.Despite the sell-off, retail investors on Stocktwits seem to view Wednesday’s crash as a buying opportunity. One user noted that 4D’s peers, Ocular Therapeutix Inc. (OCUL), Adverum Biotechnologies Inc (ADVM) and EyePoint Pharmaceuticals Inc. (EYPT), “are taking it on the chin today.”“Obviously, Nasdaq taking it hard today as well. &nbsp;Perhaps, just a general opinion of overvaluation and market fatigue? &nbsp;Very odd stock movement to me, I do expect it will reverse soon,” said Stocktwits user ‘<a href="https://stocktwits.com/ehschunk/message/579821570">ehschunk</a>’.<figure class="image"><img style="aspect-ratio:1318/454;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/FDMT_stocktwits_comment_Jul_17_88b7f49b68.png" alt="Stocktwits user ehschunk's post on FDMT stream" width="1318" height="454"><figcaption>Stocktwits user ehschunk's post on FDMT stream</figcaption></figure>The overall market sentiment didn’t help, as U.S. stocks pulled back from their all-time highs on Wednesday, impacted by falling chip and tech stocks, though the Dow Jones managed its sixth consecutive day of gains.FDMT shares are down over 19% year-to-date, contrasting with OCUL’s impressive 65% rise. EYPT has had an even tougher year, losing 57% so far, while ADVM has lost only 0.18%.However, FDMT’s consistent performance in beating EPS estimates for the past four quarters provides some relief and hope for a rebound among its retail investors.

Wall Street’s Top Loser Today Stays In Retail’s Good Books: Stocktwits Extremely Bullish On FDMT

Despite a 35% drop in shares, retail investors remain bullish on 4D Molecular Therapeutics

Wall Street’s Top Loser Today Remains In Retail’s Good Books

Equity

Despite a 35% drop in shares, retail investors remain bullish on 4D Molecular Therapeutics on promising clinical study results

Dow Surges Over 100 Points; EyePoint Pharmaceuticals Shares Plunge

Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?

EyePoint Pharmaceuticals reveals Phase 2 PAVIA trial results for Duravyu in non-proliferative diabetic retinopathy. Positive data showcases Duravyu's efficacy and safety profile.
read more...

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

- Charles Wykoff, M.D., Ph.D. joins Carl Regillo, M.D., FACS as co-chair of Scientific Advisory Board - Usha Chakravarthy, M.B.B.S, PhD., Allen Ho, M.D. FACS FASRS and Frank Holz, M.D., F.E.B.O...

EyePoint Pharmaceuticals (EYPT, $20.27) RSI Indicator left the oversold zone on April 01, 2024

This is a signal that EYPT's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

EyePoint Pharmaceuticals (EYPT, $20.27) Aroon Indicator entered a Downtrend on April 01, 2024.

For the last three days, A.I.dvisor has detected that EYPT's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

EyePoint Pharmaceuticals Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.77	--	--	N/A
Q2 '25	-$0.82	-$0.85	-3.32%	MISSED
Q1 '25	-$0.67	-$0.65	3.48%	BEAT
Q4 '24	-$0.49	-$0.64	-31.21%	MISSED
Q3 '24	-$0.55	-$0.54	1.08%	BEAT

EYPT
EyePoint Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest EYPT News

EYPT EyePoint Pharmaceuticals Inc